3D Medicines (HKSE:01244) Ending Cash Position : HK$729.0 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Ending Cash Position?

3D Medicines's Ending Cash Position for the quarter that ended in Dec. 2023 was HK$729.0 Mil.

3D Medicines's quarterly Ending Cash Position declined from Dec. 2022 (HK$778.1 Mil) to Jun. 2023 (HK$638.5 Mil) but then increased from Jun. 2023 (HK$638.5 Mil) to Dec. 2023 (HK$729.0 Mil).

3D Medicines's annual Ending Cash Position declined from Dec. 2021 (HK$948.1 Mil) to Dec. 2022 (HK$778.1 Mil) and declined from Dec. 2022 (HK$778.1 Mil) to Dec. 2023 (HK$729.0 Mil).

3D Medicines Ending Cash Position Historical Data

The historical data trend for 3D Medicines's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Ending Cash Position Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

491.08

948.11

778.06

728.97

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial			-	593.28	778.06	638.54	728.97

3D Medicines Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

3D Medicines's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	762.079	+	-33.106
	=	729.0

3D Medicines's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	638.539	+	90.434
	=	729.0

3D Medicines Ending Cash Position Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines